COST

993.89

-1.69%↓

156.68

-1.72%↓

79.49

-0.13%↓

182.55

-0.65%↓

PEP

164.35

+1.54%↑

COST

993.89

-1.69%↓

156.68

-1.72%↓

79.49

-0.13%↓

182.55

-0.65%↓

PEP

164.35

+1.54%↑

COST

993.89

-1.69%↓

156.68

-1.72%↓

79.49

-0.13%↓

182.55

-0.65%↓

PEP

164.35

+1.54%↑

COST

993.89

-1.69%↓

156.68

-1.72%↓

79.49

-0.13%↓

182.55

-0.65%↓

PEP

164.35

+1.54%↑

COST

993.89

-1.69%↓

156.68

-1.72%↓

79.49

-0.13%↓

182.55

-0.65%↓

PEP

164.35

+1.54%↑

Home・Akcijų sąrašas・USANA Health Sciences Inc

USANA Health Sciences Inc

Uždarymo kaina

18.85 -8.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.5

Max

22.08

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-17M -6.7M
Pardavimai	-22M 214M
P/E Sektoriaus vid.	23.222 32.9
Pelnas, tenkantis vienai akcijai	-0.15
Pelno marža	-3.118
Darbuotojai	1,700
EBITDA	-17M 11M

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-21

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	371K 382M
Ankstesnė atidarymo kaina	27.35
Ankstesnė uždarymo kaina	18.85

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

28.405 / 29.84 Palaikymas ir pasipriešinimas

USANA Health Sciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-18 22:31; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026-02-18 22:18; UTC

Uždarbis

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026-02-18 22:11; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026-02-18 21:52; UTC

Uždarbis

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026-02-18 23:56; UTC

Rinkos pokalbiai

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026-02-18 23:34; UTC

Rinkos pokalbiai

Uždarbis

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026-02-18 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026-02-18 23:32; UTC

Rinkos pokalbiai

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026-02-18 22:45; UTC

Uždarbis

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026-02-18 22:44; UTC

Rinkos pokalbiai

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q EPS $1.18 >NTR.T

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q Sales $5.34B >NTR.T

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q EPS $1.07 >PAAS

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q Rev $1.18B >PAAS

2026-02-18 22:30; UTC

Uždarbis

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026-02-18 22:29; UTC

Uždarbis

Kinross Gold 4Q EPS 75c >K.T

2026-02-18 22:22; UTC

Uždarbis

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026-02-18 22:22; UTC

Rinkos pokalbiai

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026-02-18 22:16; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026-02-18 22:05; UTC

Uždarbis

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026-02-18 22:03; UTC

Uždarbis

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Sales $929M >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Adj EPS 67c >KGC

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Sales $2.02B >KGC

2026-02-18 21:56; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026-02-18 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

USANA Health Sciences Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių USANA Health Sciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.405 / 29.84Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę USANA Health Sciences Inc

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.